Effects of extrafine inhaled Corticosteroid/Long-Acting β2-Agonist therapy on small airway dysfunction and type 2 inflammatory biomarkers in symptomatic patients with preserved spirometry
Completed
This study evaluates whether 4 weeks of extrafine inhaled corticosteroid/long-acting β2-agonist (beclomethasone dipropionate/formoterol fumarate, BDP/FOR) therapy improves clinical, physiological, and type 2 inflammatory outcomes compared with as-needed short-acting β2-agonist (S…
Phase 4 • Sponsor: Yi-Han Hsiao
Last updated Sep 09, 2026 17:00 UTC